Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
YunShuan Li, Quan Ren, Yali Zhou, Pingping Li, Wanhua Lin & Xiaolin Yin. (2018) Thalidomide has a significant effect in patients with thalassemia intermedia. Hematology 23:1, pages 50-54.
Read now
Read now
Karim Bayanzay & Ramsha Khan. (2015) Meta-analysis on effectiveness of hydroxyurea to treat transfusion-dependent beta-thalassemia. Hematology 20:8, pages 469-476.
Read now
Read now
Mehrnoush Kosaryan, Mandana Zafari, Abbass Alipur & Akbar Hedayatizadeh-Omran. (2014) The Effect and Side Effect of Hydroxyurea Therapy on Patients With β-Thalassemia: A Systematic Review to December 2012. Hemoglobin 38:4, pages 262-271.
Read now
Read now
Mehrnoush Kosaryan, Hossein Karami, Mandana Zafari & Negar Yaghobi. (2014) Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin 38:2, pages 115-118.
Read now
Read now
Laura Breda, Stefano Rivella, Cristina Zuccato & Roberto Gambari. (2013) Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia. Expert Review of Hematology 6:3, pages 255-264.
Read now
Read now
Roberto Gambari. (2012) Alternative options for DNA-based experimental therapy of β-thalassemia. Expert Opinion on Biological Therapy 12:4, pages 443-462.
Read now
Read now
Articles from other publishers (23)
George J. Kontoghiorghes. (2022) New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. International Journal of Molecular Sciences 23:22, pages 13990.
Crossref
Crossref
Keivan Moradi, Reza Alibakhshi, Samaneh Shafieenia & Azam Azimi. (2022) Problem of borderline hemoglobin A2 levels in an Iranian population with a high prevalence of α- and β-thalassemia carriers. Egyptian Journal of Medical Human Genetics 23:1.
Crossref
Crossref
Saqib H. Ansari, Zeeshan Hussain, Muhammad Zohaib, Sadia Parveen, Bushra Kaleem, Hina Qamar, Omair Adil, Muhammad T. Khan & Tahir S. Shamsi. (2022) A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan. Journal of Pediatric Hematology/Oncology 44:1, pages e77-e83.
Crossref
Crossref
Keivan Moradi, Aboozar Mohammadi & Mohsen Kazeminia. (2021) In silico prediction of HBD gene variants in the Iranian population. Egyptian Journal of Medical Human Genetics 22:1.
Crossref
Crossref
Mehran Karimi, Tahereh Zarei, Ardeshir Bahmanimehr, Azam Aramesh, Saeed Daryanoush & Sezaneh Haghpanah. (2021) Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience. Annals of Hematology 100:12, pages 2901-2907.
Crossref
Crossref
George Kontoghiorghes & Christina Kontoghiorghe. (2020) Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells 9:6, pages 1456.
Crossref
Crossref
Chingiz Asadov, Zohra Alimirzoeva, Tahira Mammadova, Gunay Aliyeva, Shahla Gafarova & Jeyhun Mammadov. (2018) β-Thalassemia intermedia: a comprehensive overview and novel approaches. International Journal of Hematology 108:1, pages 5-21.
Crossref
Crossref
Ali H. Algiraigri, Nicola A.M. Wright, Elizabeth Oddone Paolucci & Aliya Kassam. (2017) Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis. Hematology/Oncology and Stem Cell Therapy 10:3, pages 116-125.
Crossref
Crossref
Serena Sclafani, Alice Pecoraro, Veronica Agrigento, Antonio Troia, Rosario Di Maggio, Massimiliano Sacco, Aurelio Maggio, Elena D'Alcamo & Rosalba Di Marzo. (2016) Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures. Hematology Reports 8:4, pages 56-60.
Crossref
Crossref
Sezaneh Haghpanah, Masoomeh Esmaeilzadeh, Naser Honar, Fatemeh Hassani, Javad Dehbozorgian, Narges Rezaei, Maryam Abdollahi, Marzieh Bardestani, Sanaz Safaei & Mehran Karimi. (2015) Relationship Between Serum Hepcidin and Ferritin Levels in Patients With Thalassemia Major and Intermedia in Southern Iran. Iranian Red Crescent Medical Journal 17:5.
Crossref
Crossref
Amin Abolhasani Foroughi, Hosein Ghaffari, Sezaneh Haghpanah, Masoume Nazeri, Roghieh Ghaffari, Marzieh Bardestani & Mehran Karimi. (2015) Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea. Iranian Red Crescent Medical Journal 17:2.
Crossref
Crossref
Aikaterini Gravia, Vasiliki Chondrou, Theodora Katsila & George P. Patrinos. 2015. Preventive and Predictive Genetics: Towards Personalised Medicine. Preventive and Predictive Genetics: Towards Personalised Medicine
157
171
.
Amal El-Beshlawy, Mona El-Ghamrawy, Mona Abou EL-Ela, Fadwa Said, Sonia Adolf, Abdel-Rahman Ahmed Abdel-Razek, Rania Ismail Magdy & Amina Abdel-Salam. (2014) Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years’ follow-up in Egypt. Annals of Hematology 93:12, pages 2045-2050.
Crossref
Crossref
Maryam Khavari, Azin Hamidi, Sezaneh Haghpanah, Mohammad Hadi Bagheri, Marzieh Bardestani, Razieh Hantooshzadeh & Mehran Karimi. (2014) Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea. Iranian Red Crescent Medical Journal 16:7.
Crossref
Crossref
Aikaterini Gravia, Vasiliki Chondrou, Argyro Sgourou, Ioanna Papantoni, Joseph Borg, Theodora Katsila, Adamantia Papachatzopoulou & George P Patrinos. (2014) Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients. Pharmacogenomics 15:10, pages 1355-1364.
Crossref
Crossref
Abbas Najjari, Mohsen Asouri, Ladan Hosseini Gouhari, Haleh Akhavan Niaki, Amir Sasan Mozaffari Nejad, Seyyedeh Masoumeh Eslami, Hassan Abolghasemi, Ramin Ataee, Abdol Ali Ebrahimi, Masoumeh Rezaei Moshaei & Ali Asghar Ahmadi. (2014) α:Non–α and Gγ:Aγ globin chain ratios in thalassemia intermedia patients treated with hydroxyurea. Asian Pacific Journal of Tropical Biomedicine 4, pages S177-S185.
Crossref
Crossref
Mohammad Reza Bordbar, Samir Silavizadeh, Sezaneh Haghpanah, Roza Kamfiroozi, Marzieh Bardestani & Mehran Karimi. (2014) Hydroxyurea Treatment in Transfusion-Dependent ?-Thalassemia Patients. Iranian Red Crescent Medical Journal 16:6.
Crossref
Crossref
Mohsen S. Elalfy, Amira A. M. Adly, Eman A. Ismail, Yasmine I. Elhenawy & Islam R. Elghamry. (2013) Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. European Journal of Haematology 91:6, pages 522-533.
Crossref
Crossref
Khaled M. MusallamAli T. TaherMaria Domenica CappelliniVijay G. Sankaran. (2013) Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood 121:12, pages 2199-2212.
Crossref
Crossref
Azza AG Tantawy, Nevine G. Andrawes, Amany Ismaeil, Solaf A. Kamel & Wessam Emam. (2012) Prevalence of Xmnl Gγ polymorphism in Egyptian patients with β-thalassemia major. Annals of Saudi Medicine 32:5, pages 487-491.
Crossref
Crossref
Cristina Zuccato, Laura Breda, Francesca Salvatori, Giulia Breveglieri, Sara Gardenghi, Nicoletta Bianchi, Eleonora Brognara, Ilaria Lampronti, Monica Borgatti, Stefano Rivella & Roberto Gambari. (2012) A combined approach for ?-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction. Annals of Hematology 91:8, pages 1201-1213.
Crossref
Crossref
Mehran Karimi, Sezaneh Haghpanah, Ali Farhadi & Majid Yavarian. (2011) Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. International Journal of Hematology 95:1, pages 51-56.
Crossref
Crossref
Paolo Rigano, Alice Pecoraro, Roberta Calzolari, Antonio Troia, Santina Acuto, Disma Renda, Gaetano Restivo Pantalone, Aurelio Maggio & Rosalba Di Marzo. (2010) Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. British Journal of Haematology 151:5, pages 509-515.
Crossref
Crossref